Skip to main content
. 2018 Jul 25;9:800. doi: 10.3389/fphar.2018.00800

FIGURE 3.

FIGURE 3

Disruption of the TNF/TNFR1 interaction. Increasing concentrations of A11 (A) or A25 (B) at 0.6–80 μM and adalimumab (C) at 0.005–10 nM were used to pre-incubate human TNF (10 ng/ml) before addition on a TNFR1 substrate. Binding was measured by ELISA. Mean values (n = 2) of one experiment, representative of at least three replicates are shown.